178 related articles for article (PubMed ID: 18492755)
1. Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant.
Goldenberg N; Racine MS; Thomas P; Degnan B; Chandler W; Barkan A
J Clin Endocrinol Metab; 2008 Aug; 93(8):2953-6. PubMed ID: 18492755
[TBL] [Abstract][Full Text] [Related]
2. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
[TBL] [Abstract][Full Text] [Related]
3. Pituitary gigantism: a retrospective case series.
Creo AL; Lteif AN
J Pediatr Endocrinol Metab; 2016 May; 29(5):597-602. PubMed ID: 26887033
[TBL] [Abstract][Full Text] [Related]
4. Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
Müssig K; Gallwitz B; Honegger J; Strasburger CJ; Bidlingmaier M; Machicao F; Bornemann A; Ranke MB; Häring HU; Petersenn S
Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):198-202. PubMed ID: 17427111
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening.
Mangupli R; Rostomyan L; Castermans E; Caberg JH; Camperos P; Krivoy J; Cuauro E; Bours V; Daly AF; Beckers A
Pituitary; 2016 Oct; 19(5):507-14. PubMed ID: 27287035
[TBL] [Abstract][Full Text] [Related]
7. Experience with pegvisomant in the treatment of acromegaly.
Drake WM
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
[TBL] [Abstract][Full Text] [Related]
9. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly.
Tritos NA; Biller BM
Pituitary; 2017 Feb; 20(1):129-135. PubMed ID: 27631335
[TBL] [Abstract][Full Text] [Related]
10. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
[TBL] [Abstract][Full Text] [Related]
11. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
[TBL] [Abstract][Full Text] [Related]
13. Pegvisomant: an advance in clinical efficacy in acromegaly.
Stewart PM
Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298
[TBL] [Abstract][Full Text] [Related]
14. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study.
Marazuela M; Paniagua AE; Gahete MD; Lucas T; Alvarez-Escolá C; Manzanares R; Cameselle-Teijeiro J; Luque-Ramirez M; Luque RM; Fernandez-Rodriguez E; Castaño JP; Bernabeu I
J Clin Endocrinol Metab; 2011 Feb; 96(2):E251-9. PubMed ID: 21068147
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone receptor antagonists.
van der Lely AJ; Kopchick JJ
Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist.
Drake WM; Parkinson C; Akker SA; Monson JP; Besser GM; Trainer PJ
Eur J Endocrinol; 2001 Oct; 145(4):451-6. PubMed ID: 11581004
[TBL] [Abstract][Full Text] [Related]
19. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
